Janssen Receives Positive CHMP Opinion Recommending EDURANT(R)Black Triangle Drug (rilpivirine) for the Treatment of Adolescents Aged 12 to <18 Years with HIV-1 infection
BEERSE, Belgium, October 26, 2015/PRNewswire/ - Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a change to the terms of the marketing authorisation for EDURANT® (rilpivirine) in the European Union, to extend the indication to adolescent patients aged 12 to